Biomedicines-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2025-10-26 ms8000002977722175 来自北京

我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。
首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。
其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。
最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。

108 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2024-04-23 ms4000000323459199 来自江苏省

审稿速度:1.0 | 投稿命中率:75.0
经验分享：不难

145 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2023-12-10 ms5000001127810224 来自浙江省

审稿速度:1.0
经验分享：pending review已经10天了

161 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2026-07-19 心想事成18 来自河北省

中了必分享流程

0 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2025-06-27 ms6000000357694689 来自北京

偏重的研究方向：医学
经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢

117 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2025-06-27 ms6000000357694689 来自北京

偏重的研究方向：医学
经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢

113 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2024-10-08 隔壁李叔叔来自江苏省

各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的

172 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2025-02-24 13f4a2d1m65暂无昵称来自马里兰

偏重的研究方向：肿瘤;bioinformatics;Cancer
经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！

137 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2024-10-17 ms3000001950019838 来自湖北省

Pending大概多久呢

153 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2286182, encodeId=d824228618225, content=我去年投过这个刊，做的是中药活性成分抗肿瘤研究，从投稿到接收用了近4个月时间。 首先，研究要突出 “临床关联”，这个刊特别吃 “从基础到临床” 的逻辑。 其次，数据完整性要拉满，我当时漏了药物浓度梯度的细胞存活曲线，第一轮审稿被要求补做，多耗了20多天。 最后，参考文献要 “新旧结合”。除了经典文献，必须引用 3-5 篇该刊近 2 年发表的、和你方向相关的文章，编辑会觉得你的研究和期刊热点贴合。以上是我个分享，大家可多交流学习。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Sun Oct 26 15:33:43 CST 2025, time=2025-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200002, encodeId=73c42200002a6, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：不难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0589221513, createdName=ms4000000323459199, createdTime=Tue Apr 23 19:00:39 CST 2024, time=2024-04-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2345435, encodeId=880e234543558, content=中了必分享流程, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28e68389082, createdName=心想事成18, createdTime=Sun Jul 19 17:27:33 CST 2026, time=2026-07-19, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2271038, encodeId=8db522e103869, content=偏重的研究方向：医学 经验分享：pending review两天后就变成了pending with editor decision是不是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:35:00 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2271039, encodeId=e3a322e103963, content=偏重的研究方向：医学 经验分享：pending revuew三天后就变成pending editor decision，是要拒稿了还是正常流程呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e189183299, createdName=ms6000000357694689, createdTime=Fri Jun 27 09:53:06 CST 2025, time=2025-06-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2229785, encodeId=bcd22229e85bb, content=各位友友，这个期刊发邮件来特刊征稿，大家别信了，我投了两次，全是秒拒，特喵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210929/9d45d09216384c0abbf68ca1abb9886d/74b3e233c72b43b3910e9989453ba9a7.png, createdBy=4db65493123, createdName=隔壁李叔叔, createdTime=Tue Oct 08 12:52:03 CST 2024, time=2024-10-08, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253396, encodeId=42db2253396c4, content=偏重的研究方向：肿瘤;bioinformatics;Cancer 经验分享：收到邀稿信，给编辑发了cover letter询问能不能投，回信说投，周四投，周一拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf2a4307233, createdName=13f4a2d1m65暂无昵称, createdTime=Mon Feb 24 17:13:34 CST 2025, time=2025-02-24, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2231345, encodeId=d5ba223134586, content=Pending大概多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6dd9470622, createdName=ms3000001950019838, createdTime=Thu Oct 17 13:49:49 CST 2024, time=2024-10-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2229966, encodeId=a265222996642, content=偏重的研究方向：肿瘤;药学 经验分享：大修只给 10 天😵‍💫, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Wed Oct 09 15:16:44 CST 2024, time=2024-10-09, status=1, ipAttribution=福建省)]

2024-10-09 ms4000001640011867 来自福建省

偏重的研究方向：肿瘤;药学
经验分享：大修只给 10 天😵‍💫

164 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务